Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

1113 clinical studies listed.

Filters:

Heart Failure

Tundra lists 1113 Heart Failure clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT06809686

Study to Collect High-Resolution ECG Data and Patient Insights on Heart Failure Care

The purpose of this study is to establish an electrocardiogram (ECG) data library to facilitate future studies on heart disease. Additionally, the study will be used to monitor changes in the patient's standard of care throughout the study period and gather patient perspectives on routine diagnostic procedures and disease monitoring and feedback on the design of heart failure trials.

Gender: All

Ages: 45 Years - 80 Years

Updated: 2026-11-20

1 state

Heart Failure
RECRUITING

NCT07870395

Voice-based Outcome Identification and Clinical Evaluation in Heart Failure

VOICE-HF is a clinical study designed to evaluate the performance of a novel non-invasive software device (Noah Labs Vox) that uses vocal characteristics to estimate DHF risk and has strong potential for clinical success. This study will compare the performance of Noah Labs Vox with the contemporary performance of commonly used weight-based remote monitoring rules and applications to determine efficacy and safety.

Gender: All

Ages: 22 Years - Any

Updated: 2026-11-20

4 states

Heart Failure
Chronic Heart Failure
Chronic Heart Disease
NOT YET RECRUITING

NCT07950137

AI-ECG Screening for Early Heart Failure Diagnosis

The goal of this parallel-group cluster randomized clinical trial is to evaluate whether opportunistic screening for left ventricular systolic dysfunction (LVSD), using an artificial intelligence algorithm applied to electrocardiograms (AI-ECG), increases the detection of previously unrecognized LVSD among adults aged ≥40 years receiving routine care in primary healthcare centers within the Brazilian Public Health System. LVSD is a key finding in the diagnosis of heart failure with reduced ejection fraction (HFrEF), a condition for which effective guideline-directed medical therapies are available but which remains underdiagnosed and undertreated. The study will also evaluate the effects of AI-ECG screening on clinical management, healthcare utilization, implementation outcomes, and healthcare costs. The main questions this study aims to answer are: 1. Does adding AI-ECG screening to usual clinical assessment increase the proportion of patients with newly identified LVSD (left ventricular ejection fraction \<50%) within six months compared with clinical assessment alone? 2. Does AI-ECG screening improve the use of echocardiography, the recognition by primary care teams, and the initiation or optimization of guideline-directed medical therapy for HFrEF? 3. How do LVSD detection rates differ between patients identified through AI-ECG screening alone and those identified through clinical suspicion alone? 4. Is this screening strategy feasible, acceptable, and cost-effective when implemented in primary healthcare? Primary healthcare centers will be randomized to either an intervention group, in which AI-ECG screening results will be provided alongside the standard ECG report, or a control group receiving usual care without AI-ECG results. Participants will: 1. Undergo a routine 12-lead electrocardiogram (ECG), as clinically indicated by their primary care physician. 2. Be referred for echocardiography based on clinical suspicion of LVSD in both groups or, additionally, a positive AI-ECG screening result in the intervention group. 3. Receive educational materials about HFrEF if newly diagnosed, while participating healthcare professionals will receive educational interventions on heart failure diagnosis and management. 4. Complete questionnaires evaluating educational interventions, when applicable. 5. Be followed for six months to assess newly identified LVSD, treatment initiation and optimization, healthcare utilization (including emergency visits and hospitalizations), mortality, implementation outcomes, and healthcare costs.

Gender: All

Ages: 40 Years - Any

Updated: 2026-11-20

1 state

Heart Failure
Left Ventricular (LV) Systolic Dysfunction
RECRUITING

NCT07360158

BIO|MASTER.CorSky Family Post-market Study for the CorSky Family of ICDs

The CorSky family is BIOTRONIK´s new generation of ICDs. They are the successor devices of the current Acticor/Rivacor family and inherit all iShock/iShock\_BC (Ilivia Neo, Intica Neo) implant and programmer software features. The new features of CorSky Family are either true novel BIOTRONIK ICD features or mainly driven by unification with the Amvia pacemaker family (Amvia Edge, -Sky). The goal of the study is to confirm the safety and performance of the CorSky Family of ICDs and CRT-Ds.

Gender: All

Ages: 18 Years - 99 Years

Updated: 2026-11-20

3 states

Tachyarrhythmia
Heart Failure
ENROLLING BY INVITATION

NCT06280820

Multi-Scale Analysis of Phenotypes in Heart Failure (MAP-HEART)

Background: More than 6.5 million people in the United States live with heart failure (HF), and more than a million new cases are diagnosed each year. Treatments have improved in recent years, but researchers want to understand more about how HF develops. To do this, they need to compare blood and other samples from many people with HF. Objective: To collect blood and other samples from people with HF. These samples will be used to identify and study proteins and other factors that may lead to decreased heart function over time. Eligibility: People aged 18 years and older with heart failure. Design: Participants will be asked to join the study based on a review of their medical records. They will have 1 study visit. They will provide a blood sample: About 3 tablespoons will be collected from a needle inserted into a vein. Other tests are optional: Participants may provide urine and stool samples. They may have a cotton swab rubbed on the inside of the mouth to collect DNA. Participants may also take 3 questionnaires. They will answer questions about dietary, social, and other factors that affect their health. Participants will receive compensation. Researchers will follow the participants health by monitoring their medical records for up to 5 years.

Gender: All

Ages: 18 Years - 100 Years

Updated: 2026-11-20

2 states

Heart Failure
ACTIVE NOT RECRUITING

NCT05388097

Effect of a Quality Improvement Initiative to Address Social Determinants of Health on Rehospitalization Rates in Patients With Heart Failure

The objective of this program is to improve post-acute care coordination for necessary social services for patients leaving the hospital after recovering from an episode of decompensated heart failure.

Gender: All

Ages: 18 Years - 99 Years

Updated: 2026-11-20

2 states

Heart Failure
RECRUITING

NCT05709132

iP2P Mentorship Program for Adolescent HF Patients

The iPeer2Peer (iP2P) program is an online peer support mentorship program that provides modelling and reinforcement by trained young adult peer mentors to adolescent mentees with the same condition. A quasi-experimental single-arm pre-post study design will be employed across three sites. We will recruit 40 mentees (12-17 years of age) and 12-15 mentors (18-30 years of age) who will undergo training in mentoring and the use of eHealth technology. Mentor-mentee pairings will connect over 15 weeks through video calls and text messaging to provide peer support and encourage disease self-management skills. Data will be collected using standardized instruments and interviews across three time points.

Gender: All

Ages: 12 Years - 30 Years

Updated: 2026-11-19

1 state

Heart Failure
COMPLETED

NCT05864248

Feasibility Study SA of the Supira System for HRPCI

The objective is to assess the feasibility and safety of the Supira System in providing temporary cardiovascular hemodynamic support in patients undergoing high-risk percutaneous interventions (HRPCI).

Gender: All

Ages: 18 Years - 90 Years

Updated: 2026-11-19

Heart Diseases
Coronary Artery Disease (CAD)
Heart Failure
TERMINATED

NCT06237309

REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction

This study is researching an experimental drug called REGN5381 (called "study drug"). The study is focused on patients with heart failure with reduced ejection fraction (ie, the heart is not functioning as well as it should). The aim of the study is to see how safe, tolerable, and effective the study drug is. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-19

24 states

Heart Failure
RECRUITING

NCT07119216

The iPeer2Peer Mentorship Program for Young Adults With Heart Disease

Young adults with heart failure, including those who have undergone a heart transplant, experience considerable psychosocial stressors associated with living with a chronic illness, including heightened levels of anxiety and depression, and poor health-related quality of life compared to 'healthy' peers. Psychosocial challenges during young adulthood are especially concerning as this life stage represents a unique transitional period for fostering self-identity, friendships, mastery, and decision-making competencies. As young people with heart failure transition into adult healthcare systems, they take on greater personal responsibility due to their increasing independence and involvement in care decisions, and require more support and resources to live longer, healthier lives. Peer support provided by a person with a similar experience has been found to improve disease self-management and psychosocial health outcomes in pediatric healthcare. An established, online mentorship program, iPeer2Peer (iP2P), will be employed through a pilot feasibility waitlist randomized controlled trial with repeated measures across five sites. Sixty mentees will be recruited and randomized into intervention and control groups. Thirty mentees in the intervention group will be matched 1:1 with 20 trained mentors. These pairings will connect over 12 weeks through video calls and text messaging to provide peer support to improve self-management and psychosocial health outcomes.

Gender: All

Ages: 18 Years - 35 Years

Updated: 2026-11-19

1 state

Heart Failure
Mentorship
Peer Support
+5
RECRUITING

NCT06736574

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.

Gender: All

Ages: 18 Years - 85 Years

Updated: 2026-11-19

97 states

Heart Failure
Heart Failure With Reduced Ejection Fraction
COMPLETED

NCT06457152

Multi-Center Project: Building Electronic Tools To Enhance and Reinforce CArdiovascular REcommendations - Heart Failure

This study will test an automated, electronic health record (EHR-)embedded alert to improve prescribing of guideline-directed medical therapy for patients with heart failure and reduced ejection fraction (HFrEF). The investigators have previously tested and implemented this alert at NYU Langone Health (NYULH), and will now test and implement this alert across three other health systems.

Gender: All

Ages: 18 Years - 89 Years

Updated: 2026-11-19

4 states

Heart Failure
RECRUITING

NCT07232030

Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure

The purpose of BENEFIT-HF is to demonstrate the safety and effectiveness of Baroreflex Activation Therapy (BAT) with the Barostim System in participants with heart failure, defined as NYHA Functional Class II or III, LVEF \< 50% and NT-proBNP \< 5,000 pg/mL despite being treated with Guideline-Directed Medical Therapies (medications and devices). It includes demonstration that treatment with the Barostim System, relative to usual care medical management, reduces the rate of all-cause mortality and Heart Failure Morbidity (Cardiac Transplant, Durable LVAD, or Worsening Heart Failure Events).

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-19

16 states

Heart Failure
Heart Failure NYHA Class II
Heart Failure NYHA Class III
COMPLETED

NCT05691257

Study of the Safety and Efficacy of Roxadustat in the Treatment of Heart Failure With Chronic Kidney Disease and Anemia

The purpose of this study is to conduct a a cohort study to evaluate the efficacy and safety of the efficacy and safety of roxadustat for the treatment of anemia, quality of life and cardiac function in patients with heart failure and chronic kidney disease.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-19

Heart Failure
Chronic Kidney Diseases
Anemia
RECRUITING

NCT07601867

Effect of Dapagliflozin on Right Ventricular-Pulmonary Artery Coupling After Off-Pump Coronary Atery Bypass Grafting

This prospective, single-center observational study evaluates the effect of dapagliflozin 10 mg/day on right ventricular-pulmonary artery coupling measured by the TAPSE/PASP ratio in 72 patients with left ventricular ejection fraction \<50% after off-pump coronary artery bypass grafting (OPCAB). The primary outcome is the change in TAPSE/PASP ratio from 1 month after surgery (before dapagliflozin) to 7 months after surgery (after 6 months of dapagliflozin therapy).

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-19

1 state

Heart Failure
Coronary Arterial Disease
RECRUITING

NCT07794930

Integrating Values Based Communication in Heart Failure Management

Living with heart failure for adults over age 50 is hard. Older adults have to take many medicines to address heart failure and other health problems. That group of individuals must decide which medications to take and which devices to use to support heart health. Doctors, nurses, and social workers help patients understand these options but do not always know what is most important to them. Talking with patients about what the patients are hoping for, what the patients are worried about, and how much the patients understand about the illness is called a serious illness conversation, and it is hard to do. Doctors, nurses, and social workers are very busy and worry about upsetting patients by bringing up hard topics. The Serious Illness Care Program helps doctors, nurses, and social workers have these conversations by giving the staff a script to follow on what to say. The program also includes ways to make sure staff remember to have the conversation, a brief training, and how to document what is said during the conversation. But, nobody has studied the Serious Illness Care Program in a heart failure clinic, so it has not been customized to meet the needs of heart failure teams or older adults with heart failure. Many programs that are supposed to help patients fail in the real world. One reason is that patients do not include the needs of those who will receive and deliver it. Before this project, the team interviewed heart failure doctors, nurses, social workers, and other staff at a heart failure clinic. As well as interviewing older adults and care partners. The team asked staff how the Serious Illness Care Program can be changed to fit the needs and work in the clinic. The program includes a conversation guide that helps the team know what to say, so the study team asked patients and care partners what the thoughts on the language used and the topics covered. Then, the team practiced putting the program in place at the clinic and trained clinicians on using the Serious Illness Care Program with older adults and family members. Now the team wants to see if the heart failure team likes it and if it is doable. The team will also ask patients and care partners about the conversation and about feelings of anxiety before, during, and after the conversation. Lastly, the team will ask the individuals before and after the conversation about patients' knowledge of heart failure and how prepared the care partner feels to care for the individual. The team also want to explore how the program helps clinicians understand patients' symptoms, quality of life, and illness knowledge. Ultimately, this project establishes a structured framework to facilitate goals-of-care discussions between heart failure teams, patients, and families. These conversations empower patients to make immediate and future medical decisions aligned with personal values and lifestyle preferences. This values-based decision-making process optimizes care delivery and supports patients in achieving optimal health outcomes.

Gender: All

Ages: 18 Years - 105 Years

Updated: 2026-11-18

1 state

Heart Failure
SUSPENDED

NCT03180450

The Study of Heart Failure With Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-HF)

The purposes of the study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSC) in treating heart failure patients

Gender: All

Ages: 18 Years - 75 Years

Updated: 2026-11-18

1 state

Heart Failure
RECRUITING

NCT05873543

The Effect of a Smartphone-assisted Hybrid Cardiac Rehabilitation Program in Patients With Heart Failure.

The aim of this randomized controlled trial is to compare the impact of a case manager-led smartphone-assisted hybrid cardiac rehabilitation program with usual care in patients with HF. Participants will undergo a 12-week program led by a case manager and assisted by a smartphone. The study aims to answer two main questions: 1. Is the novel cardiac rehabilitation model feasible for patients with HF? 2. Does the intervention group show a significant improvement in exercise capacity and adherence compared to the usual care group?

Gender: All

Ages: 18 Years - 80 Years

Updated: 2026-11-18

Heart Failure
NOT YET RECRUITING

NCT07946679

Leveraging Telemedicine to Improve Guideline-Directed Medical Therapy Use and Outcomes Among Rural Patients With Heart Failure

The goal of this clinical trial is to learn if a new way of adjusting heart failure medicines can improve health in adults with heart failure who live in rural areas. This study tests whether remotely helping local doctors safely raise these doses faster can improve health over the first 3 months after leaving the hospital. The main questions it aims to answer are: * Does the new approach help participants live longer, avoid needing a heart transplant or heart pump, stay out of the hospital for heart failure, and feel better day to day, over 6 months? * Do more participants take all their recommended heart failure medicines, at the best doses, by 6 months? * Does the new approach improve quality of life and daily activity, and how well does it work in everyday rural health care? Participants will be placed by chance, like flipping a coin, into 1 of 2 groups: home monitoring alone or home monitoring plus medication optimization support. In the home monitoring alone group, participants' own doctors will manage their medicines as usual. In the medicine support group, heart failure specialists on the study team will use home readings and results from NT-proBNP blood tests, to send medicine advice to participants' own doctors. Researchers will compare the 2 groups to see if medicine support improves health and quality of life. Participants will: * Use a scale, blood pressure cuff, and activity tracker at home for 3 months * May have routine blood tests ordered by their own doctor about 2 and 6 weeks after joining, if they are in the medicine support group * Complete video or phone study visits when they join, at 3 months, and at 6 months * Answer questions about their heart failure symptoms and quality of life at each visit * Some participants may also be asked to take part in an interview about their experience.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-18

2 states

Heart Failure
Heart Failure Hospitalization
RECRUITING

NCT07749183

A Photoplethysmography-Based Machine Learning Algorithm for Early Atrial Fibrillation Detection: A Prospective Validation Study

This is a prospective study validating a new machine-learning algorithm that detects atrial fibrillation (AF) from photoplethysmography (PPG) signals, developed for integration into the Seerlinq remote monitoring platform. This algorithm builds on the same core PPG signal-processing technology as Seerlinq's HeartCore device, a CE-certified (Class IIb, MDR) device that monitors left ventricular filling pressures in heart failure patients. The algorithm will be validated through internal cross-validation, external validation against an independent cohort with paired PPG-ECG recordings, and validation in a cohort of patients with paroxysmal atrial fibrillation and frequent sinus-AF transitions.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-18

Atrial Fibrillation (AF)
Heart Failure
TERMINATED

NCT06765226

Impella Pump Return Study to Analyze Deposits and Biomaterial in Used Pumps

Analysis of cell and protein deposits on the Impella Heart Pump.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-17

2 states

Heart Failure
RECRUITING

NCT06645691

Hyperpolarized MR Imaging With Carbon-13 Pyruvate in the Human Body

Positron emission tomography with 18F fluorodeoxyglucose (FDG) is the conventional imaging technique to provide information regarding tissue glucose uptake and has been highly clinically successful. However, it cannot assess downstream metabolism, which may be useful in the diagnosis and assessment of treatment response in a variety of diseases. Patients will also be exposed to ionizing radiation, the amount of exposure can vary depending on the dose of tracer administered, frequency of scans and duration of each scan. Carbon-13 (13C) magnetic resonance imaging (MRI) is particularly attractive for metabolic imaging because carbon serves as the backbone of nearly all organic molecules in the body. With this technique, the polarization increases to approximately 30%-40%, an increase of over 10,000 to 100,000-fold, thereby dramatically increasing the MRI signal . Whilst the role of 13C imaging has been demonstrated in many sites around the world, we aim to demonstrate the feasibility and application of 13C hyperpolarized imaging in healthy Singapore residents and patients with cardiovascular and/or cardiometabolic diseases.

Gender: All

Ages: 21 Years - 99 Years

Updated: 2026-11-17

Heart Failure
Cardiometabolic Syndrome
Cancer Diagnosis
+2
RECRUITING

NCT05485376

Pulmonary Artery Catheter in Cardiogenic Shock Trial

The primary objective of the PACCS trial is to assess if early invasive hemodynamic assessment and ongoing management with a PAC in patients with cardiogenic shock due to acutely decompensated heart failure (AHDF-CS) is associated with lower in-hospital mortality risk compared to the current standard of care with no or delayed PAC assessment.

Gender: All

Ages: 18 Years - 90 Years

Updated: 2026-11-17

1 state

Cardiogenic Shock
Heart Failure
NOT YET RECRUITING

NCT07941193

Effectiveness of a Standardized Healthcare Education Program in People With Heart Failure

Heart failure is a chronic illness with a high prevalence and impact on the quality of life of the people who experience it, associated with high hospital taxes and mortality. Beyond the results of traditional clinics, factors such as health literacy, therapeutic adherence and self-healing play a key role in the evolution of this pathology. Various studies show that inadequate health literacy levels lead to better control of malaria, more re-entry and a lower quality of life. The objective of this research is to evaluate the effectiveness of a standard health education care program, led by nurses specialized in heart failure, initiating discharge from hospitals and with structured follow-up during the first few months afterward, compared to conventional care. It is intended to analyze its impact on health literacy, therapeutic adherence, self-healing, and quality of life, as well as explore the associated social determinants. It will last a random clinical trial between two groups (intervention and control) at the Heart Failure Unit of the Figueres Hospital. The participants will be adults admitted for decompensation of heart failure and will be followed for 12 months, with evaluations at admission, at 6 months and at any time after discharge. It is important to serve validated instruments to measure quality of life, health literacy and therapeutic adherence. It is hoped that the intervention will improve the quality of life and health literacy of people with heart failure, contributing to more equitable care, centered on the person and oriented towards better health outcomes.

Gender: All

Ages: 18 Years - 110 Years

Updated: 2026-11-17

Heart Failure
Nurse Led Intervention